Nature's Toolbox, Inc. (NTx Bio)


Nature’s Toolbox, Inc. (NTx Bio) is revolutionizing biomanufacturing by enabling on-demand, decentralized, and scalable production of high-quality RNA and proteins. Their mission is to democratize access to medicines by overcoming the bottlenecks of traditional, centralized manufacturing. Through proprietary, cell-free synthetic biology platforms like NTxscribe® and NTxpress®, NTx empowers researchers and companies to accelerate the development and delivery of personalized and mass-scale therapeutics, making next-generation medicine more accessible, sustainable, and efficient.

Nature's Toolbox, Inc. (NTx Bio)

Nature's Toolbox, Inc. (NTx Bio)

7701 Innovation Way NE, Rio Rancho, NM 87144


What We Do

A benchtop, automated, continuous flow RNA in vitro transcription (IVT) and purification system that produces high-integrity mRNA and saRNA in just 3 hours. Enables scalable, cost-effective, and rapid RNA manufacturing from research to commercial volumes.

A fully recombinant, cell-free protein synthesis platform designed for high-yield, high-purity protein production. Offers rapid, scalable, and reproducible protein manufacturing without the limitations of traditional cell-based or extract-based methods.

Expert mRNA synthesis services using the NTxscribe® continuous flow technology, providing high-quality, high-integrity RNA for research and discovery needs. Services include rapid turnaround, custom sequence design, and comprehensive quality control.

High-end Cryo-EM facility offering sample optimization, image acquisition, data processing, 3D analysis, training, and consulting for high-resolution structural biology research.


Regenerative Medicine


Key People

President & Chief Executive Officer

Chief Scientific Officer & Senior Vice President R&D

Chief Financial Officer

Chief Operating Officer

Senior Vice President, Business Development

Vice President, Corporate Development


News & Updates

NTx was recognized as a Top 10 Drug Discovery Company by Pharma Tech Outlook.

NTx raised $47.5 million in Series B funding to accelerate its biomanufacturing platforms.

NTx received a BARDA DRIVe contract to demonstrate its NTxscribe® platform for rapid RNA vaccine manufacturing in collaboration with Houston Methodist Hospital.

NTx is working on materials to improve global access to vaccines, supporting rapid and scalable vaccine manufacturing.

Rio Rancho Mayor discusses the positive economic impact of NTx’s presence in the region.

Site Selection Magazine features NTx as a transformative company in the biomanufacturing sector.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.